Full results of the ESSENCE–TIMI 73b trial of olezarsen in 1,349 patients with moderate hypertriglyceridaemia (fasting TG 150 mg/dL to <500 mg/dL, median 238.5 mg/dL) and elevated cardiovascular (CV) risk, presented at the congress and published simultaneously in the New England Journal of Medicine, have reinforced the topline efficacy and safety data reported earlier this year.1,2
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
